MOR — Morphosys AG Share Price
Last trade - 00:00- €2.55bn
- €2.31bn
- €238.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.79 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.93% | ||
| Return on Equity | n/a | ||
| Operating Margin | -239.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 71.76 | 327.7 | 179.61 | 278.27 | 238.28 | n/a | n/a | 25.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Directors
- Marc Cluzel CSU (60)
- Jean-Paul Kress CEO (55)
- George Golumbeski VSU (63)
- Sung Lee CFO (49)
- David Trexler CEX
- Malte Peters MGB
- Roland Wandeler MGB
- Sharon Curran IND
- Wendy Johnson IND
- Michael Brosnan SUB (66)
- Krisja Vermeylen SUB
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 30th, 1998
- Public Since
- March 9th, 1999
- No. of Employees
- 446
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Hamburg Stock Exchange
- Shares in Issue
- 37,662,738
- Address
- Semmelweisstr. 7, PLANEGG, 82152
- Web
- https://www.morphosys.com/
- Phone
- +49 89899270
- Contact
- Julia Neugebauer
- Auditors
- PwC Wirtschaftsprufung Gmbh
Similar to MOR
Vidac Pharma Holding
Hamburg Stock Exchange
FAQ
As of Today at 22:08 UTC, shares in Morphosys AG are trading at €67.75. This share price information is delayed by 15 minutes.
Shares in Morphosys AG last closed at €67.75 and the price had moved by +192.91% over the past 365 days. In terms of relative price strength the Morphosys AG share price has outperformed the FTSE Global All Cap Index by +152.84% over the past year.
There is no consensus recommendation for this security.
Find out moreMorphosys AG does not currently pay a dividend.
Morphosys AG does not currently pay a dividend.
Morphosys AG does not currently pay a dividend.
To buy shares in Morphosys AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €67.75, shares in Morphosys AG had a market capitalisation of €2.55bn.
Here are the trading details for Morphosys AG:
- Country of listing: Germany
- Exchange: HAM
- Ticker Symbol: MOR
Based on an overall assessment of its quality, value and momentum Morphosys AG is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Morphosys AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -2.57%.
As of the last closing price of €67.75, shares in Morphosys AG were trading +7.41% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Morphosys AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €67.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Morphosys AG's management team is headed by:
- Marc Cluzel - CSU
- Jean-Paul Kress - CEO
- George Golumbeski - VSU
- Sung Lee - CFO
- David Trexler - CEX
- Malte Peters - MGB
- Roland Wandeler - MGB
- Sharon Curran - IND
- Wendy Johnson - IND
- Michael Brosnan - SUB
- Krisja Vermeylen - SUB